ABSTRACT
Historically patients with advanced basal cell carcinoma have been subjected to large surgical resections for the treatment of their disease. However, with the development of vismodegib, a first in class molecule that acts to inhibit the hedgehog pathway, patients with advanced and metastatic basal cell carcinoma may have renewed hope in limiting the morbidity involved with surgery. Preliminary data shows a relatively good safety profile and promising results, although further research remains to be conducted. Current progress on utilization of vismodegib for the treatment of advanced basal cell carcinoma is reviewed in this article. Only literature with objective clinical evidence was included in this review.
Subject(s)
Anilides/therapeutic use , Carcinoma, Basal Cell/drug therapy , Pyridines/therapeutic use , Anilides/administration & dosage , Clinical Trials as Topic , Humans , Male , Pyridines/administration & dosageABSTRACT
OBJECTIVES/HYPOTHESIS: To demonstrate the efficacy of the hedgehog pathway inhibitor GDC-0449 in the treatment of advanced basal cell carcinoma. DESIGN STUDY: Case series. METHODS: Three patients treated in a referral center for locally advanced basal cell carcinoma, one with metastases, were referred for treatment in a GDC-0449 phase I clinical trial. The treatment was once per day continuous therapy with oral GDC-0449. RESULTS: Two patients showed complete clinical and radiologic resolution of disease, whereas one patient had significant reduction in tumor burden with radiologic evidence of slowly progressive local disease. Side effects were taste changes, mild to moderate hair loss, and muscle cramps in one patient. CONCLUSIONS: GDC-0449 showed significant inhibitory activity in the treatment of advanced basal cell carcinoma.
Subject(s)
Anilides/therapeutic use , Carcinoma, Basal Cell/drug therapy , Head and Neck Neoplasms/drug therapy , Hedgehog Proteins/antagonists & inhibitors , Pyridines/therapeutic use , Adult , Biopsy , Carcinoma, Basal Cell/diagnosis , Carcinoma, Basal Cell/metabolism , Diagnosis, Differential , Female , Follow-Up Studies , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/metabolism , Hedgehog Proteins/metabolism , Humans , Male , Middle Aged , Positron-Emission Tomography , Retrospective Studies , Tomography, X-Ray Computed , Treatment OutcomeSubject(s)
Carcinoma, Basal Cell/surgery , Eyelid Neoplasms/surgery , Facial Neoplasms/surgery , Frozen Sections/methods , Skin Neoplasms/surgery , Surgical Procedures, Operative/methods , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/pathology , Diagnosis, Differential , Eyelid Neoplasms/epidemiology , Eyelid Neoplasms/pathology , Facial Neoplasms/epidemiology , Facial Neoplasms/pathology , Female , Follow-Up Studies , Humans , Incidence , Intraoperative Period , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/pathology , Retrospective Studies , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Time Factors , Treatment Outcome , United States/epidemiology , Young AdultABSTRACT
OBJECTIVE: To describe new applications for the dorsal nasal flap technique of facial reconstruction. METHODS: Retrospective review of surgical records of patients in whom the dorsal nasal flap technique was used. RESULTS: The dorsal nasal flap technique was used in 61 patients to repair defects ranging in size from 12 x 17 mm to 35 x 40 mm. CONCLUSION: The dorsal nasal flap technique is more versatile than has been traditionally appreciated and can allow single-stage reconstruction of many sizes of defects affecting various areas of the nose.
Subject(s)
Rhinoplasty/methods , Surgical Flaps , Humans , Retrospective Studies , Treatment OutcomeABSTRACT
We report on two young adults with KID syndrome and follicular hyperkeratosis, hidradenitis suppurativa of the groin, progressive development of proliferative pilar cysts and dissecting cellulitis of the scalp, who developed metastatic malignant pilar tumors. Based on our findings, we believe that cancer surveillance in patients with KID syndrome should include screening for pilar tumors and their early removal to avoid development of malignant proliferating pilar tumors with poor prognosis.
